<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423943</url>
  </required_header>
  <id_info>
    <org_study_id>200513585-1</org_study_id>
    <nct_id>NCT00423943</nct_id>
  </id_info>
  <brief_title>Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia</brief_title>
  <official_title>Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This
      appears to be responsible for their difficulties in social and occupational functioning. One
      particular cognitive function that may be important for schizophrenia is called context
      processing. This refers to the ability to properly use information in the environment to
      guide thinking and behavior so that it is appropriate to the present circumstance. Problems
      with this function may explain why patients with schizophrenia think and act in unusual ways,
      and often have problems managing aspects of their lives that healthy adults take for granted.
      This cognitive function depends on a region of the brain called the prefrontal cortex, which
      shows impaired function in schizophrenia as well. Unfortunately, the biochemical aspects of
      this dysfunction are presently unknown, and it is not clear whether current psychiatric
      medications can improve this function. A recent FDA-approved medication that may improve this
      function is modafinil. Studies in animals and healthy adults show that this medication can
      improve cognitive functions which are related to context processing. We plan to study the
      effects of modafinil on context processing and the brain activity that underlies this
      function. We will use functional MRI and electrophysiology to examine the effects of
      modafinil, both after a single dose and after sustained (4 week) treatment. We predict that
      when patients receive modafinil they will perform better on cognitive tests and have improved
      activity in the regions of the brain that are responsible for these cognitive processes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a disorder of cognition. The cognitive deficits of schizophrenia are present
      at the onset of the disorder, prior to medication exposure, are persistent during periods of
      remission, and are strongly related to functional outcome. These deficits prominently include
      prefrontal-dependent functions. While existing medications effectively treat psychotic
      symptoms, they exhibit modest benefit at best for cognitive dysfunction. Studies of cognition
      in animal models indicate that the neurotransmitter systems that mediate prefrontal-dependent
      cognitive processes are not generally augmented by existing antipsychotic medications.
      Therefore, advances in the treatment of schizophrenia will require the study of agents with
      novel pharmacological profiles to establish their potential to remediate cognitive
      dysfunction.

      Advances in understanding the mechanism of action of these agents will also require the
      integration of pharmacology with a sophisticated methodology for testing cognition. This goal
      has been strongly pursued in recent years with the use of functional magnetic resonance
      imaging (fMRI) to study pharmacological effects on cognition. fMRI studies have identified
      the cortical network subserving cognitive control and working memory, which are consistently
      impaired among schizophrenia patients. The study of medication effects on these processes
      with fMRI (pharmaco-fMRI) will permit the more precise delineation of the cognitive
      mechanisms amenable to pharmacological intervention.

      This study will use fMRI to study the effects of modafinil on the functional neuroanatomy
      underlying prefrontal cognitive processes. Modafinil is an FDA-approved medication with a
      unique pharmacological profile and an increasing range of off-label indications. Its
      neurochemical effects in animal models include elevation of extracellular dopamine (DA),
      noradrenaline (NA) and glutamate in the neocortex. This profile is favorable for the
      enhancement of prefrontal cognitive processes. These neurochemical effects also appear to be
      selective for cortical versus subcortical brain regions, suggesting that modafinil may have
      minimal effects on psychotic symptoms, or extrapyramidal, autonomic and hormonal side
      effects. In addition, it differs from amphetamine in structure, neurochemical profile and
      behavioral effects, with a lower risk of addictive or cerebrovascular effects. Recent studies
      in animal models, healthy adults and adults with psychiatric and neurological disorders
      indicate that modafinil improves prefrontal cognitive functions. This suggests that modafinil
      is a leading candidate for the treatment of cognitive dysfunction in schizophrenia. We aim to
      test modafinil effects on these processes in healthy adults, in order to evaluate modafinil
      effects on normal-range cognition, and then evaluate the remediation of deficits in these
      functions in individuals with schizophrenia, both in a single-dose trial and followed by a
      trial of sustained treatment.

      Comparison 1. The effect in healthy adults and adults with schizophrenia/schizoaffective
      disorder, of Modafinil 200 milligrams single oral dose versus placebo (double-blind, balanced
      crossover design), on cognitive control task performance, and on activity of dorsolateral
      prefrontal cortical (DLPFC) during context processing, and anterior cingulate cortex (ACC)
      during conflict monitoring phases of the task, both measured by fMRI.

      Comparison 2. The effect in adults with schizophrenia/schizoaffective disorder, of 4-week
      randomized, double-blind treatment with Modafinil 200 milligrams daily versus placebo, on
      cognitive control task performance, and on activity of dorsolateral prefrontal cortical
      (DLPFC) during context processing, and anterior cingulate cortex (ACC) during conflict
      monitoring phases of the task, both measured by fMRI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Accuracy change on high-control (i.e., difficult) condition of Preparing to Overcome Prepotency (POP) Task. For high-control condition (red-cue), subjects responded in the incongruent direction (eg, for a right-pointing arrow, press the left button, and vice versa). Increased values indicate improved performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Control-related BOLD Signal Change in Locus Coeruleus</measure>
    <time_frame>4 weeks</time_frame>
    <description>BOLD signal change on high-control (i.e. difficult) condition versus low-control (i.e. easy) condition, on Preparing to Overcome Prepotency Task, measured by fMRI after 4-week treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gamma Power Change in Count of Clusters</measure>
    <time_frame>4 weeks</time_frame>
    <description>Power in Gamma frequency range by scalp electrophysiology after single-dose and after 4-week treatment: Count of Clusters (defined as those with statistically-significant Task-Related Increase, i.e. relatively larger value of wavelet coefficient in wavelet analysis of signal) for high-control (i.e. difficult) condition versus Low-control (i.e. easy) condition, in Oscillatory Power in Time-Frequency Spectrogram. Increased values indicate improved function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Positive Symptoms</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change in Average score (range 0-5) on the Scale for Assessment of Positive Symptoms (SAPS) from baseline to 4 week time-point, ranging from 0 (absent) to 5 (severe). Decreased values indicate improved clinical status (lesser symptom severity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Negative Symptoms</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change in average score, ranging from 0 (absent) to 5 (severe), on on Scale for the Assessment of Negative Symptoms (SANS) from baseline to 4-week time-point. Decreased values indicate improved clinical status (lesser symptom severity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>200 milligrams daily dose</description>
    <arm_group_label>D</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>capsule containing placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults age 18-54

          -  diagnosis of schizophrenia or schizoaffective disorder, or healthy with no personal or
             family history of mental illness

          -  able to provide informed consent

        Exclusion Criteria:

          -  history of significant head injury or other neurological illness

          -  active psychiatric illness requiring significant acute care

          -  significant intellectual impairment (e.g. standardized full-scale IQ &lt; 70)

          -  history of medical illness or treatment that either interferes with experimental
             measures (e.g. cerebrovascular disease, anemias, etc.) or is associated with
             significant increase in risk from modafinil treatment (e.g. cardiac disease)

          -  significant active substance abuse

          -  presence of ferromagnetic foreign body or prosthesis

          -  active pregnancy

          -  active treatment with medications that have drug interactions with modafinil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Minzenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cameron S Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Davis School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>August 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2017</results_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Michael Minzenberg, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cognition</keyword>
  <keyword>memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drug</title>
          <description>modafinil
modafinil: 200 milligrams daily dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
modafinil: 200 milligrams daily dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug</title>
          <description>modafinil
modafinil: 200 milligrams daily dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
modafinil: 200 milligrams daily dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="7.7"/>
                    <measurement group_id="B2" value="25.8" spread="8.9"/>
                    <measurement group_id="B3" value="26.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task</title>
        <description>Accuracy change on high-control (i.e., difficult) condition of Preparing to Overcome Prepotency (POP) Task. For high-control condition (red-cue), subjects responded in the incongruent direction (eg, for a right-pointing arrow, press the left button, and vice versa). Increased values indicate improved performance.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>modafinil
modafinil: 200 milligrams daily dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
modafinil: 200 milligrams daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task</title>
          <description>Accuracy change on high-control (i.e., difficult) condition of Preparing to Overcome Prepotency (POP) Task. For high-control condition (red-cue), subjects responded in the incongruent direction (eg, for a right-pointing arrow, press the left button, and vice versa). Increased values indicate improved performance.</description>
          <units>percent change in accuracy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="9.8"/>
                    <measurement group_id="O2" value="9.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Control-related BOLD Signal Change in Locus Coeruleus</title>
        <description>BOLD signal change on high-control (i.e. difficult) condition versus low-control (i.e. easy) condition, on Preparing to Overcome Prepotency Task, measured by fMRI after 4-week treatment.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>modafinil
modafinil: 200 milligrams daily dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
modafinil: 200 milligrams daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Control-related BOLD Signal Change in Locus Coeruleus</title>
          <description>BOLD signal change on high-control (i.e. difficult) condition versus low-control (i.e. easy) condition, on Preparing to Overcome Prepotency Task, measured by fMRI after 4-week treatment.</description>
          <units>beta coefficient of BOLD signal change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.63"/>
                    <measurement group_id="O2" value="-0.74" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gamma Power Change in Count of Clusters</title>
        <description>Power in Gamma frequency range by scalp electrophysiology after single-dose and after 4-week treatment: Count of Clusters (defined as those with statistically-significant Task-Related Increase, i.e. relatively larger value of wavelet coefficient in wavelet analysis of signal) for high-control (i.e. difficult) condition versus Low-control (i.e. easy) condition, in Oscillatory Power in Time-Frequency Spectrogram. Increased values indicate improved function.</description>
        <time_frame>4 weeks</time_frame>
        <population>2 subjects in the Drug arm refused to perform EEG.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>modafinil
modafinil: 200 milligrams daily dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
modafinil: 200 milligrams daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Gamma Power Change in Count of Clusters</title>
          <description>Power in Gamma frequency range by scalp electrophysiology after single-dose and after 4-week treatment: Count of Clusters (defined as those with statistically-significant Task-Related Increase, i.e. relatively larger value of wavelet coefficient in wavelet analysis of signal) for high-control (i.e. difficult) condition versus Low-control (i.e. easy) condition, in Oscillatory Power in Time-Frequency Spectrogram. Increased values indicate improved function.</description>
          <population>2 subjects in the Drug arm refused to perform EEG.</population>
          <units>Count of Positive Power Clusters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="12"/>
                    <measurement group_id="O2" value="17" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Positive Symptoms</title>
        <description>Change in Average score (range 0-5) on the Scale for Assessment of Positive Symptoms (SAPS) from baseline to 4 week time-point, ranging from 0 (absent) to 5 (severe). Decreased values indicate improved clinical status (lesser symptom severity).</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>modafinil
modafinil: 200 milligrams daily dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
modafinil: 200 milligrams daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive Symptoms</title>
          <description>Change in Average score (range 0-5) on the Scale for Assessment of Positive Symptoms (SAPS) from baseline to 4 week time-point, ranging from 0 (absent) to 5 (severe). Decreased values indicate improved clinical status (lesser symptom severity).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.82"/>
                    <measurement group_id="O2" value="0.58" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Negative Symptoms</title>
        <description>Change in average score, ranging from 0 (absent) to 5 (severe), on on Scale for the Assessment of Negative Symptoms (SANS) from baseline to 4-week time-point. Decreased values indicate improved clinical status (lesser symptom severity).</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>modafinil
modafinil: 200 milligrams daily dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
modafinil: 200 milligrams daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Negative Symptoms</title>
          <description>Change in average score, ranging from 0 (absent) to 5 (severe), on on Scale for the Assessment of Negative Symptoms (SANS) from baseline to 4-week time-point. Decreased values indicate improved clinical status (lesser symptom severity).</description>
          <units>units on SANS scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.04"/>
                    <measurement group_id="O2" value="2.12" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug</title>
          <description>modafinil
modafinil: 200 milligrams daily dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo
modafinil: 200 milligrams daily dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Minzenberg</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>310-825-7642</phone>
      <email>MMinzenberg@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

